Scientists probe 'Durable Effect' of MS drugs on immune system

NCT ID NCT06586177

Recruiting now Knowledge-focused Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 100 people with relapsing-remitting multiple sclerosis who are taking anti-CD20 drugs like ofatumumab or rituximab. Researchers will track changes in immune cells, proteins, and brain scans over time to understand how these therapies work long-term. The goal is to learn why some patients have better outcomes, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD20 antibodies (ofatumumab, ocrelizumab, ublituximab, rituximab)
What this could lead to: If successful, this could help doctors understand why some patients respond better to B-cell therapies and how to personalize treatment for multiple sclerosis.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING-REMITTING MULTIPLE SCLEROSIS

Contacts and locations

Locations

Heinrich-Heine University, Duesseldorf
RECRUITING

Düsseldorf, 40225, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.